The Pedro J. Romero Award recognizes individuals who have made outstanding contributions to the cancer immunotherapy field Second SITC award this year to Professor Melief who will be honoured at the 37th SITC Annual Meeting Oegstgeest, 8 September 2022 – ISA is delighted to announce that our CSO Professor Dr. Cornelis “Kees” Melief has been awarded the 2022 Pedro […]
Oegstgeest, 27 April 2022 – ISA is pleased to announce that its representatives will be participating and presenting at the following business conferences in May 2022. If you would like to meet with our team at any of these events, please contact us through the conference partnering systems or via info@isa-pharma.com. Read more…
Presentation demonstrates lead therapeutic candidate VMB-100 has the potential to address the unmet medical needs of patients suffering from Stress Urinary Incontinence Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its leadership team will be attending the RNA Leaders World Congress, taking place on the 16-17th […]
Oegstgeest, the Netherlands, February 17, 2022 – ISA Pharmaceuticals will be attending the following in person scientific and business conferences from February through to April 2022 (subject to travel restrictions), in addition to virtual conferences. Read more…
Data demonstrates first-in-class potential as a regenerative treatment of Stress Urinary Incontinence Treatment results in muscle regeneration with restored functionality in pre-clinical models Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its Chief Scientific Officer, Friedrich Metzger will be presenting data on the Company’s mRNA […]
